Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 125

1.

Missing the mark on prostate-specific antigen screening.

Miller DC, Hollenbeck BK.

JAMA. 2011 Dec 28;306(24):2719-20. doi: 10.1001/jama.2011.1879. No abstract available.

PMID:
22203542
2.

Grading the new US Preventive Services Task Force prostate cancer screening recommendation.

Volk RJ, Wolf AM.

JAMA. 2011 Dec 28;306(24):2715-6. doi: 10.1001/jama.2011.1893. No abstract available.

PMID:
22203540
3.

Prostate cancer screening--time to abandon one-size-fits-all approach?

Kim J, Davis JW.

JAMA. 2011 Dec 28;306(24):2717-8. doi: 10.1001/jama.2011.1881. No abstract available.

PMID:
22203541
4.

Prostate cancer screening--the evidence, the recommendations, and the clinical implications.

Chou R, LeFevre ML.

JAMA. 2011 Dec 28;306(24):2721-2. doi: 10.1001/jama.2011.1891. No abstract available.

PMID:
22203543
5.

USPSTF finds little evidence to support advising PSA screening in any man.

Slomski A.

JAMA. 2011 Dec 21;306(23):2549-51. doi: 10.1001/jama.2011.1804. No abstract available.

PMID:
22187266
6.

A piece of my mind. Making the call.

Welch HG.

JAMA. 2011 Dec 28;306(24):2649-50. doi: 10.1001/jama.2011.1898. No abstract available.

PMID:
22203530
7.

One man at a time--resolving the PSA controversy.

McNaughton-Collins MF, Barry MJ.

N Engl J Med. 2011 Nov 24;365(21):1951-3. doi: 10.1056/NEJMp1111894. No abstract available.

8.

Stratifying risk--the U.S. Preventive Services Task Force and prostate-cancer screening.

Schröder FH.

N Engl J Med. 2011 Nov 24;365(21):1953-5. doi: 10.1056/NEJMp1112140. No abstract available.

9.

Prostate-cancer screening--what the U.S. Preventive Services Task Force left out.

Brett AS, Ablin RJ.

N Engl J Med. 2011 Nov 24;365(21):1949-51. doi: 10.1056/NEJMp1112191. No abstract available.

10.

Risks of PSA screening now better understood.

Peres J.

J Natl Cancer Inst. 2013 Nov 6;105(21):1590-2. doi: 10.1093/jnci/djt328. No abstract available.

PMID:
24142893
11.

2008 US Preventive Services Task Force recommendations and prostate cancer screening rates.

Prasad SM, Drazer MW, Huo D, Hu JC, Eggener SE.

JAMA. 2012 Apr 25;307(16):1692-4. doi: 10.1001/jama.2012.534. No abstract available.

PMID:
22535850
12.

The United States Preventive Services Task Force recommendation against prostate-specific antigen screening--point.

Ablin RJ.

Cancer Epidemiol Biomarkers Prev. 2012 Mar;21(3):391-4. doi: 10.1158/1055-9965.EPI-12-0058. No abstract available.

13.

Preventive Services Task Force recommends against PSA screening after age 75.

Twombly R.

J Natl Cancer Inst. 2008 Nov 19;100(22):1571-3. doi: 10.1093/jnci/djn422. No abstract available.

14.

PSA screening: the USPSTF got it right.

Lefevre M.

J Fam Pract. 2013 Nov;62(11):617, 619. No abstract available.

PMID:
24288702
15.

The science and art of prostate cancer screening.

Yao SL, Lu-Yao GL.

J Natl Cancer Inst. 2011 Mar 16;103(6):450-1. doi: 10.1093/jnci/djr047. No abstract available.

PMID:
21350220
16.

Comment on the US Preventive Services Task Force's draft recommendation on screening for prostate cancer.

Kwiatkowski M, Klotz L, Hugosson J, Recker F.

Eur Urol. 2012 Apr;61(4):851-4. doi: 10.1016/j.eururo.2012.01.023. No abstract available.

PMID:
22285762
17.

Clinical practice. Screening for prostate cancer.

Hoffman RM.

N Engl J Med. 2011 Nov 24;365(21):2013-9. doi: 10.1056/NEJMcp1103642. Review. No abstract available.

18.

PSA test not recommended by Canadian Task Force.

Tanday S.

Lancet Oncol. 2014 Dec;15(13):e589. doi: 10.1016/S1470-2045(14)71111-8. No abstract available.

PMID:
25499287
19.

Informed consent for prostate-specific antigen screening.

Wilkinson S, Chodak G.

Urology. 2003 Jan;61(1):2-4. No abstract available.

PMID:
12559252
20.

Informed consent for prostate-specific antigen screening.

Catalona WJ.

Urology. 2003 Jan;61(1):17-9. No abstract available.

PMID:
12559258

Supplemental Content

Support Center